Sterilized Multipotent Cell Compositions for Stored Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic methods for tissue repair, particularly using autologous stem cells, are inconvenient and risky due to the need for multiple surgical procedures, potential immune responses, and the risk of viral transmission, limiting their effectiveness in treating tissue injuries and diseases.
Innovation Solution
Development of novel compositions comprising sterilized and virus-inactivated multipotent cells or microvascular tissue, which can be stored and administered without culturing, offering angiogenic and anti-inflammatory properties for allogeneic or xenogeneic use, and can be formulated with implantable scaffolds for tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous stem cells are used for tissue repair, then therapeutic efficacy is improved, but treatment convenience and safety deteriorate due to multiple surgical procedures and viral transmission risks
Solution Approach 1:
The patent uses allogeneic stem cells as a substitute (copy) for autologous stem cells. The allogeneic cells are harvested from healthy donors, expanded, and differentiated into various tissue types in vitro, then transplanted to replace damaged tissues. This copying approach eliminates the need for harvesting autologous cells while providing similar therapeutic effects.
Solution Approach 2:
The patent performs preliminary actions by harvesting, expanding, and differentiating stem cells into desired tissue types before transplantation. The cells are prepared in advance under controlled conditions, screened for viruses, and stored for later use. This preliminary preparation eliminates the need for multiple surgical procedures and reduces treatment time.
2Ease of operation
If allogeneic stem cells are used for tissue repair, then treatment convenience is improved, but immune response and rejection risk increase
Solution Approach 1:
The patent converts the potential harm of immune rejection into a benefit by using immunosuppressive drugs to control the immune response. The immunosuppressive therapy, while having side effects, prevents graft rejection and allows the allogeneic cells to engraft and function. This controlled immune suppression transforms the harmful immune response into a manageable condition that enables successful transplantation.
3Quantity of substance
If stem cells are cultured and expanded, then cell quantity is improved, but treatment time and cost increase
Solution Approach 1:
The patent performs preliminary cell expansion and differentiation in vitro before transplantation. Large numbers of stem cells are harvested from donors, expanded through multiple passages in culture, and differentiated into specific tissue types (bone, cartilage, tendon, ligament, muscle, fat, skin, nerve, blood vessels) before being stored and later transplanted. This preliminary expansion provides sufficient cell quantities for clinical use.
4Reliability
If multiple surgical procedures are performed for autologous cell harvesting and transplantation, then therapeutic efficacy is improved, but patient morbidity and cost increase
Solution Approach 1:
The patent replaces the complex multi-step autologous cell harvesting and transplantation process with a simpler allogeneic cell transplantation procedure. The allogeneic cells are pre-prepared in the lab, eliminating the need for surgical harvesting from the patient. This copying approach maintains therapeutic efficacy while significantly reducing procedural complexity and patient morbidity.
Data Source
AI summary
The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.